期刊文献+

长期应用葡激酶衍生体对大鼠凝血、纤溶系统影响的研究 被引量:2

Influence of Long-used Staphylokinase Derivative on Hemoagglutinative and Fibrinolytic Systems
下载PDF
导出
摘要 本研究探讨葡激酶衍生体(SAKD)对正常和高脂喂养大鼠的凝血及纤溶系统的影响及葡激酶衍生体使用的安全性。将正常和模型大鼠各30只分别分为生理盐水组、SAKD组、重组葡激酶(rSAK)组,按照0.5mg/kg体重给药,3天1次,连续15次,观察出血情况,监测用药前后出血时间(BT)、血小板计数(BPC)、部分活化凝血酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)、纤维蛋白原(Fg)、D-二聚体(D-D)、纤溶酶原活性(PLG)、纤溶酶抑制物活性(PI)。结果发现,正常大鼠中SAKD组有1例轻微出血,rSAK组有2例,但均可自行止血;高脂模型组大鼠中SAKD组有2只轻微出血,rSAK组中有3只轻微出血;各组大鼠的血小板计数、D-D、PLG、PI值无明显改变。SAKD处理的高脂组大鼠的APTT、PT、TT值明显延长,Fg减少(p<0.05),SAKD对正常动物出凝血影响较小,但能够改善高血脂大鼠的高凝血状态。结论:本试验剂量的SAKD具有较好的安全性,长期使用能减轻高脂大鼠血液的高凝症状。 This study was aimed to explore the influence of staphylokinase derivative (SAKD) on the hemoagglutinative and fibrinolytic systems, and to determine the safety of the staphylokinase derivative in application. The normal and model rats each 30 were divided into normal saline, SAKD and rSAK groups. The hemorrhage, blecding time (BT), blood platelet count (BPC), activated partial thromboplastin time (APTT), prothrombin time ( PT), thrombin time ( TT), fibronogen ( Fg ), D-dimer ( D-D ), plasminogen (PLG) and plasmininhibitor activity (PI) were detected before and after the administration with staphylokinase derivative 0.5 mg/kg body weight, once three days for consecutive 15 days. The results indicated that one case of normal rats with SAKD and two cases of high fat diet model group had mild hemorrhage, all of which showed automatic hemostasis; and 3 cases in rSAK group had mild hemorrhage. And the platelet counting, D-D, PLG and PI in all groups did not significantly change. The rats of high fat diet group treated with SAKD showed the significant extension of APTT, PT and TT times, and the decrease of Fg time (p 〈 0.05). All the experimental results demonstrated that the influence of SAKD on the hemagglutination of the normal animals was lower, however, which can improve the high-hemagglutination status of the rats with high fat diet. It is concluded that the SAKD at the dosage of this study has the higher safety, which can alleviate the high hemagglutination symptoms of the rats with high fat diet.
出处 《中国实验血液学杂志》 CAS CSCD 2009年第3期670-673,共4页 Journal of Experimental Hematology
基金 国家新药重大专项资助课题
关键词 葡激酶衍生体 纤维蛋白选择性溶栓剂 凝血系统 纤溶系统 staphylokinase derivative fibrin-selective thrombolytic agent hemoagglutination-fibrinolytic system
  • 相关文献

参考文献10

  • 1王旻,王圆圆,邹民吉,徐涛,刘深,吴琛,王嘉玺,徐东刚.新型低抗原性葡激酶的构建、表达及功能分析[J].军事医学科学院院刊,2007,31(2):118-121. 被引量:4
  • 2王园园,王旻,邹民吉,刘深,徐涛,蔡欣,王金凤,徐东刚.重组SAK及其突变体多克隆抗体制备及应用研究[J].医学研究杂志,2007,36(12):37-39. 被引量:3
  • 3桑国卫.我国创新药物和中药现代化研究近况[J].中国药事,2007,21(1):3-7. 被引量:6
  • 4沈涛.血浆脂蛋白对凝血及纤溶活性的影响[J].中国动脉硬化杂志,2003,11(1):77-80. 被引量:14
  • 5Reiner AP,Siscovick DS,Rossendaal FR.Hemostatic risk factors and arterial thrombotic disease.Thromb Haemost,2001,85:584-595
  • 6Thompson WD,Smith EB.Atherosclerosis and coagulation system.J Pathol,1989,159:97-106
  • 7Leinoe EB,Hoffmann MH,Kjaersgaard E,et al.Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function.Br J Haematol,2005,128:526-532
  • 8Hara A.Kawamoto T,Matsumom K,et al.Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease.Pathophysiol Haomost Thromb,2006,35:388-391
  • 9Moreadith RW,Collen D.Clinical development of PEGylated recombinant staphylokinase(PEG-Sak)for bolus thrombolytic treatment of patients with acute myocardial infarction.Adv Drug Deliv Rev,2003,55:1337-1345
  • 10Tbogersen AM,Jansson JH,Boman K,et al.High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precedea first acute myocardial infarction in both men and women:evidence for the fibrinolytic system as an independent:primary risk factor.Circulation,1998,98:2241-2247

二级参考文献19

  • 1李伍举,应晓敏.BioSun:计算机辅助分子生物学实验设计的软件系统[J].军事医学科学院院刊,2004,28(5):401-404. 被引量:28
  • 2范萍,刘秉文.内源性高甘油三酯血症患者血浆VLDL、LDL及HDL脂质与载脂蛋白组成的研究[J].华西医科大学学报,1995,26(1):6-10. 被引量:10
  • 3王旻,王圆圆,邹民吉,徐涛,刘深,吴琛,王嘉玺,徐东刚.新型低抗原性葡激酶的构建、表达及功能分析[J].军事医学科学院院刊,2007,31(2):118-121. 被引量:4
  • 4Collen D,Schlott B,Enqelborqhs Y,et al.On the mechanism of the activation of human plasminogen by recombinant staphylokinase[J].Biol Chem,1993,268(11):8284-8289.
  • 5Sakai M,Watanuki M,Matsuo O.Mechanism of fibrin-specific fibrinolysis by staphylokinase:participation of α2-plasmin inhibitor[J].Biochem Biophys Res Commun,1989,162(2):830-837.
  • 6Vanderschueren S,Barrios L,Kerdsinchai P,et al.A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction[J].Circulation,1995,92(8):2044-2049.
  • 7Vanderschueren S,Dens J,Kerdsinchia P,et al.Randomized coronary potency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction[J].Am Heart J,1997,134(2):213-219.
  • 8Lijnen HR,Van HB,Vandenbossche L,et al.Biochemical properties of natural and recombinant staphyIokinase[J].Fibrinolysis,1992,6(1):214-225.
  • 9Collen D,Franks DC,Jean S,et al.Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons[J].Circulation,1993,87(3):996-1006.
  • 10Declerck PJ,Vanderschueren S,Billiet J,et al.Prevalence and induction of circulating antibodies against recombinant staphylokinase[J].Thromb Haemost,1994,71(1):129-133.

共引文献21

同被引文献10

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部